Having trouble accessing articles? Reset your cache.

Zibotentan fails prostate cancer Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said once-daily oral zibotentan ( ZD4054)

Read the full 100 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE